2026 → 2037 · A path to EOD 2037

A decade to change
a lifetime.

Dario Amodei argues that AI could help defeat most diseases within 5–10 years of powerful AI arriving. Machines of Loving Grace ↗ We call that goal End Of Disease (EOD) 2037: a median lifespan of 100 by 2037.

Reaching EOD 2037 would require a 20× acceleration in mortality improvement compared to today. Here is a scenario for how that could happen.

USA · Median lifespan

USA median lifespan: linear extrapolation versus 20× accelerationUnited States, average of male and female period medians. Gray line: observations, 2003–2023. Linear extrapolation: 84.2 years in 2037. The same 20× acceleration as What it would take: at least 100.0 years. Mortality above age 100 is not modeled.80859095100200320102025203720× acceleration2037 targetCalendar year
Linear extrapolation20× acceleration
USA · average of male and female period medians. Gray: observed, 2003–2023. Linear: lifespan trend excluding 2020–2022. The 20× curve is identical to What it would take ↗ with USA selected and acceleration set to 20×. Projections begin in 2025; age-100 bounds are shown at 100, not a biological ceiling.

The scenario

One path to EOD 2037, in five stages.

The stages run from discovery in 2026 to longer lives in 2037, with three milestones each. This scenario is hypothetical, based on the mortality projections and analysis in Forecasts & analysis ↗.

Stage 12026–2028AI Discoveries

AI finds cracks in biology’s hardest problems.

In the next two years, we predict that AI will become a scientist, moving from answering questions to generating testable biological insight. Three main inflection points will drive this change.

  • AI makes its first fundamental discoveries

    AI-driven findings appear in Cell, Nature, and Science, with important results independently replicated.

  • Automated research becomes the norm

    Research systems connect biomedical datasets, build biological models, and use experimental results to choose the next hypothesis.

  • Early AI-designed drugs outperform

    Matched comparisons show AI-designed programs reaching validated candidates or first human trials significantly faster, without sacrificing candidate quality.

Stage 1 / AI Discoveries

The AI-driven research loop

Every result changes the next question.

Learning is a loop, not a pipelineBiological data informs a model. The model selects an experiment. Measured results return to the data, including results that disagree with the prediction.01 · Data02 · Model03 · ExperimentlearnpredictupdateA useful surpriseimproves the model.
Learn from biological data

Connect molecular measurements, cell behavior, and patient outcomes. Each experiment informs the next prediction.

Stage 22029–2030Biomedicine Scales

Research investment doubles. Promising ideas scale up.

By 2029–2030, we predict that AI discoveries will become a predictable output of data generation. That will make basic biology far more investable, much as scaling laws made it easy to justify scaling language models. Three shifts will follow.

  • 2× funding with shared infrastructure.

    Total biomedical research funding doubles from 2026. Government, academia, pharma, and AI companies establish large public data-generation consortia.

  • New drug submissions soar to record highs

    Applications for human testing and marketing approval reach record levels, and the FDA implements AI-driven review to accelerate development.

  • Digital organisms begin to show promise

    Models linking molecules, cells, tissues, and organs begin predicting unseen experimental results and treatment responses, guiding the next generation of therapies.

Chart sources

Research!America / TEConomy (2026), Table 1 ↗. All-sector U.S. medical and health R&D, not just NIH; includes pandemic funding. Adjusted using BLS CPI-U ↗. 2026 holds the 2025 estimate flat in real terms; the dashed curve doubles it by 2030.

Stage 2 / Biomedicine Scales

U.S. biomedical research funding

2×

The research engine, doubled by 2030.

+18.9% per year · 2026–2030

Annual funding · billions of 2025 dollars

U.S. medical and health R&D: historical funding and a doubling scenarioHistorical estimates for 2021–2025, adjusted to 2025 dollars. The 2025 estimate of $297.5 billion is held flat to a modeled 2026 baseline, then grows exponentially by 18.9% annually to $595.0 billion in 2030. Future growth is assumed, not fitted to history.02004006002021: $346.7 billion in 2025 dollars2022: $343.7 billion in 2025 dollars2023: $320.5 billion in 2025 dollars2024: $319.6 billion in 2025 dollars2025: $297.5 billion in 2025 dollars$595B$297B20212023202620282030
Historical estimatesExponential scenario

One shared research infrastructure

One shared research infrastructureGovernment, academia, pharma, and AI labs all contribute to one shared public data infrastructure. Conceptual illustration.GovernmentAcademiaPharmaAI labsShared public data
Stage 32031–2032AI-first Healthcare

AI becomes part of everyday healthcare.

In 2031–2032, we predict that frontier AI labs will go full-stack, bringing healthcare directly to the consumer. AI will diagnose disease and prescribe drugs, managing each patient’s personalized healthcare journey. To keep up, the FDA will revolutionize how drugs are tested and approved.

  • Breakthrough cancer drugs approved at phase 2

    Selected AI-designed therapies gain accelerated or conditional approval after compelling phase II results, with continuing safety and confirmatory studies.

  • Frontier AI labs open personalized healthcare clinics

    Licensed clinicians and AI systems work together on personalized prevention, diagnosis, treatment, and follow-up. Each clinic runs its own experimental lab, imaging, genomics, and blood testing, and stays connected to patients through wearables and on-demand check-ins.

  • A single-trial pathway from preclinical work to approval

    For validated applications, in silico models outperform animal models. Human-cell and tissue experiments lead directly into monitored human testing; selected therapies qualify for approval on one rigorous trial.

Stage 3 / AI-first Healthcare

AI moves to the center of care.

Diagnosis, prescriptions, and follow-up in one place, informed by the data patients choose to share.

AI clinicrun by afrontier labExperimental labMRI and imagingGenomicsBlood testsWearablesDiagnoseOn-demandcheck-insPrescribeHealth recordsFollow up
Stage 42033–2034Disease Control

Diseases become chronic conditions to be managed, rather than a source of early death.

By 2033–2034, we predict that better models and adaptable treatments will begin changing what is treatable. Three advances will mark the turn.

  • Full-stack AI clinics reach half of America as a subscription service

    50% of Americans subscribe directly to AI clinics run by frontier AI labs, rather than paying for insurance. The clinics now provide the whole stack: they design tailored drugs, manufacture them, and deliver the care.

  • Cancer becomes a chronic condition

    Early diagnosis catches cancers before they turn invasive. Repeated diagnosis and simultaneous targeting of multiple vulnerabilities then allow treatments to adapt before options run out.

  • Replacement organs address loss of organ function

    Rather than treating the disease, we replace the organ. Breakthroughs in surgical delivery and in stem-cell manufacturing and growth enable lab-grown hearts, livers, and other organs to address irreversible organ failure.

Stage 4 / Disease Control

Personalized cancer interception.

From each tumor, tailored drugs are synthesized to intercept it.

Tumor profiledTailored drugssynthesizedCancer intercepted

Early diagnosis enables continuous, real-time monitoring. Each time the tumor changes, new drugs are designed and made to match it.

Stage 52035–2037Health as a Right

A new frontier of health

From 2035 to 2037, we predict that the ambition will move beyond treating individual diseases to extending healthy life. Three milestones will close the decade.

  • Anti-aging therapies target late-life frailty and comorbidity

    Therapies reduce frailty and disability, extending healthy life into the oldest ages.

  • A median lifespan of 100

    Anti-aging therapies and other advances lower late-life mortality enough to bring period median lifespan to 100.

  • Health becomes a human right

    Health becomes a guarantee, not just access to treatment. When someone falls ill with a condition that has no good treatment, AI spins up the lab research and drug development needed to treat them. Society commits to that work for every person, whatever the illness and whoever the patient.

Stage 5 / Health as a Right

Health is a human right.

If you get sick, AI spins up the research to treat you.

Guaranteed for every personYou get sickWith any illness, at any age.AI spins up lab research (if necessary)Experiments begin on your condition.A treatment is madeDesigned and manufactured for you.Health is restoredFollow-up continues until you recover.